Cancer Cell APC and Open Access: The $10,400 Fee Nobody's Deal Covers

Cancer Cell is a hybrid journal:

1. Subscription track (default, $0): Your article is published behind the Elsevier/Cell Press paywall. Readers access it through library subscriptions. You pay nothing.
2. Gold OA track ($10,400): Your article is immediately free to read under a Creative Commons license (CC BY or CC BY-NC-ND).

Most Cancer Cell authors publish via subscription. The journal's readership is concentrated in cancer research centers, oncology departments, and pharma R&D groups, nearly all of which have institutional access. Publishing behind the paywall doesn't meaningfully limit who reads your paper in this community.

The open access question becomes relevant when your funder mandates it or when you want broader reach beyond the traditional oncology subscriber base.

This is the central issue with Cancer Cell's open access model. Cell Press journals sit outside the scope of most Elsevier transformative agreements.

Elsevier has negotiated Read & Publish deals with over 800 institutions worldwide. These agreements cover APCs for more than 1,800 Elsevier hybrid journals. But the exclusion list typically includes Cell Press, The Lancet, and Clinics titles. Cancer Cell falls squarely into the excluded category.

What this means in practice:

A handful of institutions have recently negotiated Cell Press inclusion. The UC system's expanded Elsevier agreement (2025) added Cell Press and Lancet coverage, with the library covering a portion of the APC. But this remains the exception. If you're at a European university with a strong Elsevier deal, don't assume it covers Cancer Cell. Ask your library specifically.

Cell Press has a less transparent waiver process than Springer Nature. Here's what exists:

Geographical pricing (GPOA):

Elsevier's Geographical Pricing for Open Access applies to Cancer Cell. Authors from lower-income countries receive a "personalized APC" that accounts for their country tier and institutional affiliation. Discounts range from 25% to 100% depending on the country classification. The system calculates this automatically during the payment process.

Financial hardship waivers:

Cancer Cell considers case-by-case waiver requests. Contact the Cell Press editorial office after acceptance if you need support. Approval isn't guaranteed, and the success rate isn't publicly disclosed. Cell Press is generally viewed as less systematic about waivers than Springer Nature, which has a clear, published framework tied to Research4Life classifications.

No society discounts:

The American Association for Cancer Research (AACR), which publishes its own journals, doesn't have an APC discount arrangement with Cell Press. AACR membership won't reduce your Cancer Cell APC.

Cancer Cell supports both CC BY and CC BY-NC-ND licenses. Plan S requires CC BY. If your funder is a cOAlition S member, you must select CC BY at the licensing stage. CC BY-NC-ND won't satisfy Plan S compliance.

For NCI-funded and NIH-funded oncology researchers: the green OA route is free. Publish via subscription, deposit the accepted manuscript in PMC after 12 months. This satisfies federal public access policy without any APC. The 12-month embargo clock starts from the publication date, not the acceptance date.

Cancer Cell focuses on research that reveals cancer mechanisms with clear therapeutic implications. The editorial bar is high and specific:

• Molecular and cellular mechanisms of cancer initiation, progression, and metastasis
• Tumor immunology and immunotherapy mechanisms
• Cancer metabolism and microenvironment
• Drug resistance mechanisms and therapeutic vulnerabilities
• Translational studies bridging basic cancer biology and clinical application

Cancer Cell desk-rejects approximately 70-75% of submissions. The editors look for mechanistic depth that goes beyond descriptive genomics or correlative studies. A large sequencing study that catalogs mutations but doesn't explain their functional significance won't make it past the editors, regardless of sample size.

The journal published approximately 150-180 original research articles in 2024. It's selective, but less so than Nature Medicine or NEJM.

Cancer Cell doesn't charge submission fees, page fees, or color figure charges. But watch for these:

• Tax on top of APC: EU VAT adds 15-25% to the listed $10,400. In Germany (19% VAT), the effective cost is $12,376. In France (20% VAT), it's $12,480.
• Graphical abstract: Cancer Cell requires a graphical abstract for all research articles. If you hire a scientific illustrator, budget $200-$500. Most labs create these in-house using BioRender or similar tools ($300/year subscription).
• License lock-in: If you select CC BY-NC-ND and later realize your funder requires CC BY, changing the license post-publication requires publisher approval. This process is slow and not guaranteed.
• Embargo timing: The 12-month green OA embargo runs from the online publication date, not the acceptance date. If your paper spends 3 months in production, the total time from acceptance to public access is 15 months.
• Supplementary figure costs: Cancer Cell papers often have extensive supplementary materials. While the journal doesn't charge for these, preparing 10-20 supplementary figures with proper formatting takes time and money that isn't captured in the APC.

For most Cancer Cell authors, the decision framework is:

1. Check with your library first. Ask specifically: "Does our Elsevier agreement cover Cell Press journals?" Don't assume it does.
2. Funder requires immediate OA? If yes and no institutional coverage, pay $10,400 from grant funds. Budget for taxes.
3. NCI/NIH-funded, no OA mandate? Publish via subscription (free). Deposit in PMC after 12 months. This satisfies federal policy.
4. Choosing between Cancer Cell and Nature Cancer? If your institution has Springer Nature R&P, Nature Cancer's OA is free to you despite its higher listed APC. Factor institutional coverage into your journal choice.
5. No mandate, no deal? Publish via subscription. Cancer Cell's subscriber base covers virtually every cancer research institution globally.

Getting accepted at Cancer Cell is harder than paying for it. The editors want mechanistic cancer biology that changes how the field thinks about a therapeutic target or resistance pathway. If you want to check whether your manuscript meets that bar before submitting, run a free readiness scan to identify gaps in your paper's mechanistic depth and framing.

For the latest APC information and author guidelines, visit the Cancer Cell author information page.